MARKET

KZR

KZR

Kezar Life Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.54
+0.20
+3.75%
Opening 13:09 01/22 EST
OPEN
5.27
PREV CLOSE
5.34
HIGH
5.54
LOW
5.26
VOLUME
68.85K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
2.180
MARKET CAP
256.33M
P/E (TTM)
-4.4228
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporat...
BusinessWire · 01/07 18:02
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 12/18/2020 08:13
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Kezar Life Sciences (KZR) has been added to the NASDAQ Biotech Index, effective Dec. 21, 2020 before market open.In the past year, the stock has gained 103.7% vs. 23.8% gains
Seekingalpha · 12/14/2020 21:20
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Business Wire · 12/14/2020 21:01
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI)...
BusinessWire · 12/14/2020 18:01
Is KZR A Good Stock To Buy Now?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are indust...
Insider Monkey · 12/14/2020 15:46
Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtu...
Business Wire · 11/12/2020 21:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZR. Analyze the recent business situations of Kezar Life Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KZR stock price target is 14.67 with a high estimate of 18.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 24.79M
% Owned: 53.58%
Shares Outstanding: 46.27M
TypeInstitutionsShares
Increased
28
1.45M
New
28
-206.09K
Decreased
27
1.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.63%
Key Executives
Chairman/Independent Director
Jean-Pierre Sommadossi
President/Chief Scientific Officer/Director
Christopher Kirk
Chief Executive Officer/Director
John Fowler
Chief Financial Officer/Secretary
Marc Belsky
Senior Vice President
Vassiliki Economides
Other
Noreen Henig
Independent Director
Franklin Berger
Independent Director
Graham Cooper
Independent Director
Jason Dinges
Independent Director
Elizabeth Garner
Independent Director
Michael Kauffman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
More

Webull offers kinds of Kezar Life Sciences Inc stock information, including NASDAQ:KZR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZR stock methods without spending real money on the virtual paper trading platform.